Eli Lilly (NYSE:LLY) today announced positive safety and efficacy data for its investigational once-weekly insulin efsitora alfa (efsitora). The QWINT-1, QWINT-3 and QWINT-4 Phase 3 clinical trials evaluated efsitora in adults with type 2 diabetes … [Read More...] about Lilly to submit once-weekly insulin for regulatory review this year following strong clinical results
Main Content
Sponsored Content
Introduce New Drug Delivery Medical Devices with Lower Risk and Higher ROI
Manufacturing automation is crucial to achieving the precision, quality, and volume required in the medical device industry. Advanced robotics, AI, modular designs, and wireless technology offer the … [Read More...] about Introduce New Drug Delivery Medical Devices with Lower Risk and Higher ROI
Featured Posts
A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
Glucotrack (Nasdaq:GCTK) believes it can tap into a diabetes market that includes millions of people who aren't being served completely. That's according to the company's Chief Scientific Officer, Mark Tapsak, who gave a presentation on the … [Read More...] about A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
Dexcom continues advances in AI for CGM, type 2 diabetes awareness
As one of the leaders in continuous glucose monitoring (CGM) technology, Dexcom (Nadsaq:DXCM) continues to expand its capabilities. The company has hit a number of milestones recently, including updated CGMs, new AI capabilities, expanded … [Read More...] about Dexcom continues advances in AI for CGM, type 2 diabetes awareness
Tandem continues to deliver more options, benefits for those with diabetes
It's been a busy couple of years for Tandem Diabetes Care (Nasdaq:TNDM) and it doesn't look like slowing down any time soon. The San Diego-based automated insulin delivery system developer offers two differentiated pump platforms — the … [Read More...] about Tandem continues to deliver more options, benefits for those with diabetes
Breaking: Sequel to launch twiist automated insulin delivery system next month
Sequel Med Tech announced at the American Diabetes Association's 85th Scientific Sessions in Chicago that it plans to launch its twiist system in July. Dr. Joanna Mitri, the company's chief medical officer, shared the update in a Product Theater … [Read More...] about Breaking: Sequel to launch twiist automated insulin delivery system next month
Dexcom shares U.S. report on CGM benefits for type 2 diabetes
Dexcom (Nasdaq:DXCM) has shared a new report highlighting access and attitudes toward type 2 diabetes in the U.S. The company released its report — "Dexcom State of Type 2 Report: Access and Attitudes Across the United States" — ahead of the … [Read More...] about Dexcom shares U.S. report on CGM benefits for type 2 diabetes
Study backs Tandem automated insulin delivery in pregnant women with type 1 diabetes
A new study showed improved glucose control in pregnant women using Tandem Diabetes Care (Nasdaq:TNDM) insulin delivery technology. The study showed that pregnant women with type 1 diabetes stayed in the target glucose range for pregnancy more … [Read More...] about Study backs Tandem automated insulin delivery in pregnant women with type 1 diabetes
Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
Medtronic (NYSE:MDT) today shared data supporting the use of its MiniMed 780G automated insulin delivery system in a range of patients. The medtech giant highlighted improved glycemic outcomes for those with type 2 diabetes and in young children. … [Read More...] about Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
Abbott could pave new roads in diabetes management with dual sensor on the horizon
About three years ago, Abbott (NYSE:ABT) announced that it had a new diabetes-related biowearable under development. The technology — a dual sensor that continuously monitors glucose and ketone levels — already had FDA breakthrough device … [Read More...] about Abbott could pave new roads in diabetes management with dual sensor on the horizon
Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
Tandem Diabetes Care (Nasdaq:TNDM) announced today that its t:slim X2 system now works with the Abbott (NYSE:ABT) FreeStyle Libre 3 Plus. This marks the latest pairing of automated insulin delivery (AID) and continuous glucose monitor (CGM) … [Read More...] about Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
Ypsomed and CamDiab announced today that they agreed to integrate their mylife Loop automated insulin delivery system with a future Abbott (NYSE:ABT) sensor. The companies plan to pair their pump system with the Abbott dual glucose-ketone sensor, … [Read More...] about Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
In case you missed it
- PharmaSens, SiBionics collab on all-in-one insulin patch pump
- Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor
- CeQur hits insulin patch milestone, highlights commercial expansion
- Zyno recalls certain infusion pumps due to software issue
- Ypsomed, CamDiab continue global insulin pump iPhone software rollout
- Dexcom has a Class I CGM receiver recall
- Medtronic to invest $50M in India Diabetes center
- Flat Medical partners with Mercury Medical on smart syringe distribution
- Glucotrack to effect a reverse stock split
- Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
- Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
- Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
- Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor
- Mosanna launches with $80M to support nasal spray for obstructive sleep apnea
- Roche, IBM collab on predictive AI for CGM tech
Clinical Trials
Lilly to submit once-weekly insulin for regulatory review this year following strong clinical results
Eli Lilly (NYSE:LLY) today announced positive safety and efficacy data for its investigational once-weekly insulin efsitora alfa (efsitora). The QWINT-1, QWINT-3 and QWINT-4 Phase 3 clinical trials evaluated efsitora in adults with type 2 diabetes who used insulin for the first time, previously used daily basal insulin, and previously used daily basal insulin and mealtime insulin, […]
Study finds MannKind inhaled insulin safe, effective for children
New study results demonstrated the safety and efficacy of the MannKind Afrezza inhaled insulin offering for children with type 1 diabetes. Investigators presented findings from the INHALE-1 study as a symposium at the American Diabetes Association’s 85th Scientific Sessions. The data showed that inhaled insulin offers a safe and effective replacement for rapid-acting meal insulin […]
A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
Glucotrack (Nasdaq:GCTK) believes it can tap into a diabetes market that includes millions of people who aren’t being served completely. That’s according to the company’s Chief Scientific Officer, Mark Tapsak, who gave a presentation on the company’s long-term implantable continuous blood glucose monitor (CBGM) as part of the American Diabetes Association’s 85th Scientific Sessions’ “Innovation […]
Study backs Tandem automated insulin delivery in pregnant women with type 1 diabetes
A new study showed improved glucose control in pregnant women using Tandem Diabetes Care (Nasdaq:TNDM) insulin delivery technology. The study showed that pregnant women with type 1 diabetes stayed in the target glucose range for pregnancy more with the Tandem t:slim X2 automated insulin delivery system with Control-IQ technology compared to standard insulin delivery with injections […]
Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
Medtronic (NYSE:MDT) today shared data supporting the use of its MiniMed 780G automated insulin delivery system in a range of patients. The medtech giant highlighted improved glycemic outcomes for those with type 2 diabetes and in young children. Investigators shared data at the American Diabetes Association’s 85th Scientific Sessions in Chicago. In one study, participants […]
